Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature
Open Access
- 27 December 2017
- journal article
- review article
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 10 (1) , 2018027
Abstract
Breastfeeding in patients with chronic myeloid leukaemia (CML) who take tyrosine kinase inhibitors (TKIs) is not recommended but interruption of TKI treatment may cause the loss of remission. We observed the kinetics of the leukaemic clone in 3 women with CML in accordance with treatment interruptions for pregnancy and breastfeeding. The concentrations of nilotinib and imatinib in maternal milk were measured when the breastfeeding period was over. Nilotinib transfer into human breast milk was demonstrated for the first time and had a maximum concentration (Cmax) 129 ng/ml after 4 hours of the drug intake at a dose of 400 mg. The Cmax of imatinib in maternal milk ranged from 420 to 1411 ng/ml after 4-8 hours of the drug intake at a dose of 400-600 mg. Breastfeeding without TKI treatment may be safe with molecular monitoring, but preferably in those patients with CML who have durable deep molecular response.Keywords
This publication has 20 references indexed in Scilit:
- The impact of dasatinib on pregnancy outcomesAmerican Journal of Hematology, 2015
- Managing pregnancy in chronic myeloid leukaemiaAnnals of Hematology, 2015
- Growth deceleration in children treated with imatinib for chronic myeloid leukaemiaEuropean Journal of Cancer, 2014
- Managing children with chronic myeloid leukaemia (CML)British Journal of Haematology, 2014
- TYROSINE KINASE INHIBITORS AND PREGNANCYMediterranean Journal of Hematology and Infectious Diseases, 2014
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 2013
- Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemiaPediatric Blood & Cancer, 2012
- Imatinib in breast milkAnnals of Hematology, 2009
- Imatinib use during pregnancy and breast feeding: a case report and review of the literatureArchives of Gynecology and Obstetrics, 2008
- Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milkJournal of Perinatology, 2007